GNTA צמיחת רווחי EPS רבעונית Genenta Science
Future revenues for Genenta Science S.p.A. (GNTA) rely on the sale of gene modification methods for treating brain tumors. Historical quarterly EPS growth reflects the current dynamics of this process, with the latest mark standing at 48.40. The business's success is tied to the safety of interferon delivery and patient survival rates. Meanwhile, the company strictly adheres to biomaterial disposal regulations within its laboratories.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_GNTA_-_Genenta-Science-S.p.A._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "genenta.com (GNTA): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 04.11.2026 | 👁️GURU.Markets👁️")
Genenta Science S.p.A. (GNTA) - פילוחי מדדים ודוחות פיננסיים
High development costs for cancer cell therapies make Genenta Science S.p.A. (GNTA) sensitive to capitalization efficiency, as reflected in the current quarterly EPS growth rate. This indicator measures the dynamics of net income per share, allowing investors to assess the actual speed of innovation monetization and business resilience amid fierce competition in the rare tumor market.
